Transcript of Earnings Conference Call - Q2FY2027
AI summary
- Q2FY27 consolidated revenue grew 63% y-y to INR181 Cr; EBITDA margin 27.5%; PAT doubled to INR29 Cr
- H1 FY27 revenue INR343 Cr; FY27 revenue guidance revised upwards to INR720 Cr+
- European-GMP certification received for cephalosporin and oncology facility; 19 bioequivalence studies completed
- Acquisition of 4 acres for Unit 7 manufacturing facility; Unit 7 to commercialize 200 BE products by FY30
- Working capital cycle improved; debtor days reduced from 208 to 178
- FY28 revenue expected INR950-1000 Cr; FY29 target INR1,000 Cr+ with 25-30% growth
- Hormone and biologics segments to contribute INR100-150 Cr and INR80-100 Cr respectively by FY29
- EBITDA margin guidance 27-28% at INR720-750 Cr revenue; 29-30% margin possible beyond INR1,000 Cr
- Capex of INR140-150 Cr planned for FY27; INR500-600 Cr over 3 years for expansions; funded mainly by internal accruals
- Multiple analyst queries on bioequivalence pipeline, regulatory approvals, and margin sustainability addressed
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 KPL — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add KPL to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Kwality Pharmaceuticals Limited
Important.
The summary above is generated automatically from Kwality Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.